Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.36 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.36 |
| ▸ | PDE5A | O76074 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.33 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.33 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.33 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.33 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26134079 | 0.90 | MEN1 (0.37) | TRPV1KDRALDH1A1MEN1KMT2A | |
| SCHEMBL30605929 | 0.90 | MEN1 (0.37) | TRPV1KDRALDH1A1MEN1KMT2A | |
| SCHEMBL3882959 | 0.88 | GAA (0.37) | TRPV1PDE5AKDRALDH1A1MEN1 | |
| SCHEMBL4556465 | 0.88 | PDE5A (0.39) | TRPV1PDE5AKDRALDH1A1MEN1 | |
| SCHEMBL1127585 | 0.82 | MEN1 (0.42) | TRPV1ALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL18616818 | 0.81 | TRPV1 (0.35) | TRPV1ALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL3888574 | 0.81 | TRPV1 (0.34) | TRPV1ALDH1A1KDM4ESHMT1SHMT2 | |
| SCHEMBL1127143 | 0.81 | SLC40A1 (0.46) | — | |
| SCHEMBL23458147 | 0.81 | MAPK13 (0.35) | TRPV1KMT2AMAPK13MAPK12MAPK11 | |
| SCHEMBL31443297 | 0.81 | RAB9A (0.33) | TRPV1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024227104-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BRAF VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| US-20230303551-A1 | N-CYCLYL-SULFONAMIDES USEFUL FOR INHIBITING RAF | ALBERT EINSTEIN COLLEGE OF MEDICINE | 2023-09-28 | — | — | US | disclosed |
| EP-4196228-A1 | N-CYCLYL-SULFONAMIDES USEFUL FOR INHIBITING RAF | Albert Einstein College of Medicine (US) | 2023-06-21 | — | — | EP | disclosed |
| WO-2022036176-A1 | N-CYCLYL-SULFONAMIDES USEFUL FOR INHIBITING RAF | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2022-02-17 | — | — | WO | disclosed |
| US-10421761-B2 | Compounds for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2019-09-24 | — | — | US | disclosed |
| US-20190263796-A1 | LIM KINASE INHIBITORS, PHARMACEUTICAL COMPOSITION AND METHOD OF USE IN LIMK-MEDIATED DISEASES | CELLIPSE (FR) | 2019-08-29 | — | — | US | disclosed |
| EP-3515909-A1 | LIM KINASE INHIBITORS, PHARMACEUTICAL COMPOSITION AND METHOD OF USE IN LIMK-MEDIATED DISEASES | Cellipse (FR) | 2019-07-31 | — | — | EP | disclosed |
| US-20180099975-A1 | COMPOUNDS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2018-04-12 | — | — | US | disclosed |
| WO-2018055097-A1 | LIM KINASE INHIBITORS, PHARMACEUTICAL COMPOSITION AND METHOD OF USE IN LIMK-MEDIATED DISEASES | CELLIPSE (FR) | 2018-03-29 | — | — | WO | disclosed |
| US-20170073341-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | NOVARTIS AG (CH) | 2017-03-16 | — | — | US | disclosed |
| EP-2282636-B1 | BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS | NOVARTIS AG (CH) | 2016-03-23 | — | — | EP | disclosed |
| US-9233956-B2 | Benzene sulfonamide thiazole and oxazole compounds | NOVARTIS AG (CH) | 2016-01-12 | — | — | US | disclosed |
| WO-2014194127-A1 | COMPOUNDS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2014-12-04 | — | — | WO | disclosed |
| US-20140080851-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | GLAXOSMITHKLINE LLC (US) | 2014-03-20 | — | — | US | disclosed |
| US-8642759-B2 | Benzene sulfonamide thiazole and oxazole compounds | GLAXOSMITHKLINE LLC (US) | 2014-02-04 | — | — | US | disclosed |
| US-20130144055-A1 | Benzene Sulfonamide Thiazole And Oxazole Compounds | GLAXOSMITHKLINE LLC (US) | 2013-06-06 | — | — | US | disclosed |
| US-8415345-B2 | Benzene sulfonamide thiazole and oxazole compounds | Glaxo SmithKline LLC (US) | 2013-04-09 | — | — | US | disclosed |
| EP-2498608-A1 | BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS | GlaxoSmithKline LLC (US) | 2012-09-19 | — | — | EP | disclosed |
| US-20090298815-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | NOVARTIS AG (CH) | 2009-12-03 | — | — | US | disclosed |
| WO-2009137391-A2 | BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303551-A1 | N-CYCLYL-SULFONAMIDES USEFUL FOR INHIBITING RAF | BRAF, RAF1, NRAS | TRPV1 2294/4885SUCNR1 155/4885PDE5A 4577/4885 |
| US-20190263796-A1 | LIM KINASE INHIBITORS, PHARMACEUTICAL COMPOSITION AND METHOD OF USE IN LIMK-MEDIATED DISEASES | LIMK1, LIMK2, LMTK3 | TRPV1 3590/4885SUCNR1 3997/4885PDE5A 2391/4885 |
| US-20170073341-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | STS, TST, TPST2 | TRPV1 377/4885SUCNR1 958/4885PDE5A 2922/4885 |
| US-20140080851-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | STS, TST, TPST2 | TRPV1 377/4885SUCNR1 958/4885PDE5A 2922/4885 |
| US-10421761-B2 | Compounds for kinase modulation, and indications therefor | MAP3K20, MAP3K13, MAP3K8 | TRPV1 3795/4885SUCNR1 1856/4885PDE5A 1895/4885 |
| US-20130144055-A1 | Benzene Sulfonamide Thiazole And Oxazole Compounds | STS, TST, TPST2 | TRPV1 377/4885SUCNR1 958/4885PDE5A 2922/4885 |
| US-20090298815-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | STS, TST, TPST2 | TRPV1 377/4885SUCNR1 958/4885PDE5A 2922/4885 |
| US-20180099975-A1 | COMPOUNDS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | TRPV1 3795/4885SUCNR1 1856/4885PDE5A 1895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.